Share This Page
Suppliers and packagers for eryc
✉ Email this page to a colleague
eryc
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Dr Reddys Labs Sa | ERYC | erythromycin | CAPSULE, DELAYED REL PELLETS;ORAL | 050536 | NDA AUTHORIZED GENERIC | Dr. Reddy's Labratories Inc. | 75907-076-01 | 100 CAPSULE, DELAYED RELEASE PELLETS in 1 BOTTLE, PLASTIC (75907-076-01) | 2024-09-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Eryc
Introduction
Eryc, a branded form of erythromycin, is a widely prescribed macrolide antibiotic used to combat bacterial infections. As a critical medication in infectious disease management, understanding its supplier landscape offers insights into procurement strategies, market competition, and supply chain resilience. This comprehensive overview examines key suppliers, manufacturing considerations, and industry dynamics pertaining to Eryc.
Overview of Eryc and Its Market
Eryc, primarily marketed by Pfizer, is based on erythromycin, a naturally occurring macrolide antibiotic discovered in the 1950s. The drug targets bacterial protein synthesis, effective against a broad spectrum of organisms, including respiratory, skin, and gastrointestinal pathogens [1]. Given its longstanding presence, both originators and generic manufacturers supply erythromycin-based products.
The global erythromycin market faced challenges due to patent expirations, manufacturing complexities, and the increasing adoption of newer antibiotics. Despite these factors, Eryc maintains a significant share within specific therapeutic niches.
Key Suppliers and Manufacturers of Erythromycin (Eryc)
1. Pfizer Inc.
Role: Originator and primary supplier of Eryc.
Manufacturing capabilities: Pfizer's erythromycin manufacturing plants are located in the United States, Ireland, and other strategic regions. The company's scale ensures consistent quality and supply reliability [2].
Market positioning: As the original developer, Pfizer holds robust distribution channels, authorized generics, and regulatory approvals in key markets.
2. Teva Pharmaceutical Industries Ltd.
Role: Leading generic manufacturer.
Manufacturing capabilities: Teva produces erythromycin tablets and suspensions through its global manufacturing network, emphasizing cost-effective production and wide availability [3].
Market positioning: Teva's extensive generic portfolio and competitive pricing position it as a significant erythromycin supplier, especially in emerging markets.
3. Mylan N.V. (Now part of Viatris)
Role: Major generic erythromycin provider.
Manufacturing capabilities: Mylan has manufacturing sites in Europe, Asia, and North America, focusing on large-scale production of erythromycin formulations [4].
Market positioning: Known for affordability and broad distribution, Mylan’s erythromycin products are accessible worldwide.
4. Lupin Limited
Role: Indian generic manufacturer.
Manufacturing capabilities: Lupin operates facilities in India and internationally, producing erythromycin in various forms, including tablets and topical formulations [5].
Market positioning: Lupin supplies erythromycin to Asian, African, and Latin American markets, often at lower price points.
5. Other Notable Suppliers
- G Pharmaceutical (Glenmark Pharmaceuticals): Produces erythromycin formulations, primarily targeting Asian markets.
- Pharmacia & Upjohn (now part of Pfizer): Historically involved in erythromycin marketing, though relics of legacy products remain.
Manufacturing and Supply Chain Dynamics
Manufacturing Challenges
Producing erythromycin requires complex fermentation processes, with strict control over purity and potency. These technical demands can limit the number of reliable suppliers, impacting overall market supply. Regulatory compliance adds further barriers, ensuring only manufacturers with rigorous quality controls maintain market entry.
Supply Chain Resilience
Global dependence on a handful of large producers raises concerns over supply disruptions. Recent shortages in erythromycin have been linked to manufacturing issues, regulatory delays, and raw material shortages [6].
Diversification of suppliers and strategic stockpiling have become essential for healthcare providers and governments.
Market Trends and Influencing Factors
- Patent Expirations & Generic Entry: The expiration of Pfizer’s erythromycin patents opened markets for generics, intensifying competition.
- Emerging Markets: Lower manufacturing costs in India and China have increased erythromycin availability.
- Regulatory Environment: Compliance with FDA, EMA, and other agencies influences supplier participation.
- Antimicrobial Stewardship: Growing efforts to curb antibiotic resistance impact demand patterns.
Regulatory and Quality Considerations
Ensuring compliance with international Good Manufacturing Practices (GMP) and obtaining approvals from agencies like the FDA and EMA remain prerequisites for suppliers. The safety profile of erythromycin also necessitates rigorous quality controls, which can exclude lower-quality producers from the supply chain.
Conclusion
The supply landscape for Eryc pivots around a few key players, notably Pfizer as the originator and multiple global generics manufacturers, including Teva, Mylan (Viatris), and Lupin. Manufacturing complexities, regulatory standards, and market dynamics shape this ecosystem. Stakeholders must monitor supply chain stability, regulatory shifts, and competitive actions to ensure continuous access to erythromycin formulations.
Key Takeaways
- Market Dominance: Pfizer remains the primary supplier of Eryc, leveraging its patent history and manufacturing infrastructure.
- Generics’ Role: Companies like Teva, Mylan (Viatris), and Lupin dominate the generic erythromycin market, offering cost-effective alternatives.
- Supply Risks: Manufacturing complexities and regulatory hurdles pose risks to supply stability; diversification is vital.
- Market Trends: Patent expirations and the rise of emerging markets expand the supplier base but heighten competition.
- Regulatory Vigilance: Quality assurance and compliance with GMP standards remain critical in maintaining supplier credibility.
FAQs
1. Who are the main suppliers of erythromycin-based drugs like Eryc?
Pfizer is the original manufacturer of Eryc, with major generic suppliers including Teva, Viatris (Mylan), and Lupin.
2. How has patent expiration affected erythromycin supply?
Patent expirations have facilitated the entry of numerous generics, increasing availability but also intensifying market competition.
3. What manufacturing challenges are associated with erythromycin?
The fermentation process requires precise control, and raw material supply, quality assurance, and regulatory compliance can impact production stability.
4. Are there regional differences in erythromycin suppliers?
Yes, Indian and Chinese manufacturers dominate the emerging markets, while Pfizer and other Western firms primarily serve high-income regions.
5. What should healthcare providers consider when sourcing erythromycin?
They should assess supplier quality, regulatory compliance, supply chain stability, and pricing to ensure consistent and safe medication supply.
References
[1] World Health Organization. Antibiotics: Erythromycin. WHO reports, 2021.
[2] Pfizer Inc. Product Information: Eryc. Pfizer Corporate Website, 2022.
[3] Teva Pharmaceuticals. Generics Portfolio. Teva Annual Report, 2022.
[4] Viatris (formerly Mylan). Global Product Lines. Viatris Press Release, 2022.
[5] Lupin Limited. Operational Overview. Lupin Annual Report, 2022.
[6] U.S. Food and Drug Administration. Erythromycin Shortage Notices, 2021.
More… ↓
